Live Breaking News & Updates on Prnewswire Neuraxpharm Group
Stay updated with breaking news from Prnewswire neuraxpharm group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acquisition of Brain Therapeutics with operations in Greece, Cyprus and the Balkan countries DUSSELDORF, Germany and BARCELONA, Spain, March 8, 2022 /PRNewswire/ Neuraxpharm Group (Neuraxpharm) ....
/PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces. ....
Neuraxpharm selected for prestigious pilot program to supply medical cannabis in France Neuraxpharm strengthens its position as a European leader in medical cannabis with the pilot program issued by The National Agency for the Safety of Medicines and Health Products DÜSSELDORF, Germany and BARCELONA, Spain, Jan. 28, 2021 /PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces that its affiliate Neuraxpharm France has been selected as one of winners for the participation in a pilot program for the medical use of cannabis issued by The French National Agency for the Safety of Medicines and Health Products (ANSM), together with Panaxia Labs, Israel s largest medical cannabis manufacturer. ....
Neuraxpharm launches first product in Japan - First buccal midazolam to receive approval in Japan, world s second largest central nervous system market [1] DÜSSELDORF, Germany and BARCELONA, Spain, Jan. 12, 2021 /PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the launch in Japan of the recently acquired prescription brand Buccolam (oromucosal midazolam) following its approval as the first buccally administered formulation for the treatment of status epilepticus (SE) in the country. The launch follows the completion of Neuraxpharm s acquisition of Buccolam from Takeda Pharmaceutical Company Limited (Takeda) in September and represents the expansion of Neuraxpharm s footprint outside Europe into Japan, the third largest pharmaceutical market in the world ....
Share: DÜSSELDORF, Germany and BARCELONA, Spain, Dec. 14, 2020 /PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on disorders of the central nervous system (CNS), today announces the expansion of its operations in Northwestern Europe with the launch of Neuraxpharm Ireland, and the acquisition of Medinutrix Ltd (trading as Aribamed), a privately-owned specialty pharmaceutical distribution company. With this acquisition, Neuraxpharm now has both the platform and the local expertise to launch new products in the Irish market for the first time, and will start to build its position as a CNS specialist in the Republic of Ireland. Neuraxpharm will leverage its CNS expertise to make available suitable products, out of its extensive portfolio, including the recently acquired market-leading Buccolam ....